Login to Your Account



Financings NEWS
In a two-step scheme, specialty vaccine developer Paxvax Inc. acquired the FDA-approved oral typhoid vaccine Vivotif from Crucell Switzerland AG and financed the deal with $50 million in secured debt from an investment fund managed by Pharmakon Advisors and $12 million in an extension of its series B preferred stock.

Ophthamology specialist Ocular Therapeutix Inc. downsized its initial public offering (IPO), raising $65 million through the sale of 5 million shares sold at $13 each instead of the company's desired $14 to $16.

Gene therapy specialist Applied Genetic Technologies Corp. (AGTC) banked new funds with a stock sale of 2 million shares priced at $15 each, for a net haul of $30 million, following by several months an initial public offering (IPO) that pulled down $50 million.
More Financings Headlines

Cast Your Vote

Has biotech’s bubble burst?: